Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-27 · accession 0001209191-24-005117 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-27 | 2024-03-27 | VKTX | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +221.7K | 2.42M | +10% | $0 | |
| 2024-03-27 | 2024-03-27 | VKTX | Lian Brian | Pres, CEO, Dir | F - Tax | $83.34 | -153.9K | 2.27M | -6% | -$12.83M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2024-03-27 | A | A | 221,667 | $0.00 | 2,420,401 | D | — | — | (F1) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal. |
| 2 | Common | Common Stock, par value $0.00001 per share | 2024-03-27 | F | D | 153,948 | $83.34 | 2,266,453 | D | — | — | (F2) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. |